Total Payments
$17,811
2024 Payments
$3,779
Companies
88
Transactions
921
Medicare Patients
6,032
Medicare Billing
$1.9M
Payment Breakdown by Category
Food & Beverage$17,243 (96.8%)
Education$567.69 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,243 | 906 | 96.8% |
| Education | $567.69 | 15 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,316 | 73 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,291 | 85 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,197 | 82 | $0 (2024) |
| Janssen Biotech, Inc. | $893.61 | 45 | $0 (2024) |
| Amgen Inc. | $793.77 | 34 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $784.10 | 41 | $0 (2024) |
| PFIZER INC. | $762.80 | 53 | $0 (2024) |
| Genentech USA, Inc. | $681.52 | 41 | $0 (2024) |
| Astellas Pharma US Inc | $621.90 | 21 | $0 (2024) |
| Lilly USA, LLC | $585.99 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,779 | 171 | Novartis Pharmaceuticals Corporation ($296.61) |
| 2023 | $3,399 | 148 | Novartis Pharmaceuticals Corporation ($380.30) |
| 2022 | $2,613 | 131 | Janssen Biotech, Inc. ($196.74) |
| 2021 | $1,725 | 97 | Merck Sharp & Dohme Corporation ($163.75) |
| 2020 | $635.08 | 37 | E.R. Squibb & Sons, L.L.C. ($87.90) |
| 2019 | $1,723 | 99 | Merck Sharp & Dohme Corporation ($238.79) |
| 2018 | $1,696 | 106 | Merck Sharp & Dohme Corporation ($177.98) |
| 2017 | $2,242 | 132 | Amgen Inc. ($210.33) |
All Payment Transactions
921 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: HORMONE THERAPY | ||||||
| 12/27/2024 | Ipsen Biopharmaceuticals, Inc | — | Education | In-kind items and services | $99.00 | General |
| 12/27/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $27.71 | General |
| 12/23/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $27.70 | General |
| 12/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Oncology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.66 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL | Food and Beverage | In-kind items and services | $29.66 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.66 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Genetically Defined Disease | ||||||
| 12/06/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $18.28 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.54 | General |
| 12/04/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $13.97 | General |
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $5.48 | General |
| Category: Oncology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.95 | General |
| Category: Oncology | ||||||
| 11/25/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.94 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.97 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.67 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.54 | General |
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $10.55 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,496 | 41,516 | $2.7M | $645,755 |
| 2022 | 41 | 1,728 | 67,171 | $2.6M | $587,014 |
| 2021 | 28 | 1,284 | 20,369 | $1.1M | $315,612 |
| 2020 | 39 | 1,524 | 18,465 | $1.6M | $336,116 |
Total Patients
6,032
Total Services
147,521
Medicare Billing
$1.9M
Procedure Codes
144
All Medicare Procedures & Services
144 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 6,400 | $940,200 | $278,426 | 29.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 3,840 | $271,260 | $70,975 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 107 | 298 | $157,940 | $41,992 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 222 | 364 | $145,600 | $34,552 | 23.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 16 | 24 | $98,880 | $31,194 | 31.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 69 | 290 | $110,200 | $28,612 | 26.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 231 | $158,466 | $24,899 | 15.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 13 | 1,400 | $104,600 | $23,135 | 22.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 16 | 21,000 | $105,000 | $18,398 | 17.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 92 | 105 | $78,750 | $14,933 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 184 | 215 | $58,050 | $14,154 | 24.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 180 | $48,600 | $11,703 | 24.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 16 | 24 | $15,312 | $9,929 | 64.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $23,560 | $5,351 | 22.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 98 | $29,792 | $5,004 | 16.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 71 | $14,555 | $4,205 | 28.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 13 | 17 | $12,884 | $4,086 | 31.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 46 | 162 | $24,624 | $3,834 | 15.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $17,980 | $3,623 | 20.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 28 | $14,280 | $2,911 | 20.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 48 | 204 | $21,420 | $2,618 | 12.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 44 | $14,696 | $2,366 | 16.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 53 | 187 | $17,391 | $2,089 | 12.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 58 | $9,048 | $1,363 | 15.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 18 | 61 | $5,490 | $1,343 | 24.5% |
About Dr. Mauna Pandya, MD
Dr. Mauna Pandya, MD is a Hematology & Oncology healthcare provider based in Oak Lawn, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356439178.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mauna Pandya, MD has received a total of $17,811 in payments from pharmaceutical and medical device companies, with $3,779 received in 2024. These payments were reported across 921 transactions from 88 companies. The most common payment nature is "Food and Beverage" ($17,243).
As a Medicare-enrolled provider, Pandya has provided services to 6,032 Medicare beneficiaries, totaling 147,521 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 144 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oak Lawn, IL
- Active Since 10/10/2006
- Last Updated 07/30/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356439178
Products in Payments
- KEYTRUDA (Biological) $1,126
- OPDIVO (Biological) $927.42
- KISQALI (Drug) $434.57
- Lenvima (Drug) $416.53
- Nplate (Biological) $364.91
- DARZALEX (Biological) $328.98
- IBRANCE (Drug) $273.51
- VERZENIO (Drug) $224.06
- Trodelvy (Drug) $205.74
- INJECTAFER (Drug) $204.67
- XARELTO (Drug) $203.88
- OXBRYTA (Drug) $198.58
- REBLOZYL (Biological) $193.53
- ERLEADA (Drug) $190.86
- LIBTAYO (Biological) $190.51
- CYRAMZA (Drug) $180.77
- ULTOMIRIS (Biological) $177.92
- IMBRUVICA (Drug) $177.63
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $177.17
- Doptelet (Drug) $177.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oak Lawn
Amar Hamad, Md, MD
Hematology & Oncology — Payments: $150,395
Hematology & Oncology $150,395
Dr. Rami Haddad, Md, MD
Hematology & Oncology — Payments: $63,926
Hematology & Oncology $63,926
Ghassan Zalzaleh, Md, MD
Hematology & Oncology — Payments: $49,226
Hematology & Oncology $49,226
Vasantha Kumaraiah, Md, MD
Hematology & Oncology — Payments: $5,422
Hematology & Oncology $5,422
Prashant Joshi, M.d, M.D
Hematology & Oncology — Payments: $4,830
Hematology & Oncology $4,830
Dr. Rajalaxmi Mckenna, M.d, M.D
Hematology & Oncology — Payments: $1,445
Hematology & Oncology $1,445